107 results
PRER14A
BXRXQ
Baudax Bio, Inc.
25 Aug 23
Preliminary revised proxy
4:01pm
may not gain the acceptance of the public or the medical community. Negative public reaction to cell-based immunotherapy in general and a recent … reimbursement rates. CMS surveys and publishes retail community pharmacy acquisition cost information in the form of National Average Drug Acquisition
424B5
BXRXQ
Baudax Bio, Inc.
18 Aug 23
Prospectus supplement for primary offering
4:40pm
market acceptance for ANJESO and any of our other product candidates once approved;
the acceptance of ANJESO by the medical community, including
DEFA14A
EX-99.1
BXRXQ
Baudax Bio, Inc.
9 Aug 23
Additional proxy soliciting materials
5:28pm
of setting Medicaid reimbursement rates. CMS surveys and publishes retail community pharmacy acquisition cost information in the form of National Average … covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services
DEFA14A
EX-99.2
BXRXQ
Baudax Bio, Inc.
9 Aug 23
Additional proxy soliciting materials
5:28pm
of the public or the medical community. Negative public reaction to cell-based immunotherapy in general and a recent increase in patient deaths and clinical
8-K/A
EX-99.2
hl2svrnm6k ro03gshu
9 Aug 23
Other Events
5:27pm
8-K/A
EX-99.1
0olb3gdlypckl4j52e
9 Aug 23
Other Events
5:27pm
DEFA14A
gzk8vq71cs9wyj 2s3rl
5 Jul 23
Additional proxy soliciting materials
5:28pm
8-K
EX-2.1
wuj3s3jijhf24t1jwn
5 Jul 23
Entry into a Material Definitive Agreement
5:26pm
424B3
3avrc qulcy83g
28 Apr 23
Prospectus supplement
4:02pm
424B3
hd5y15tg3w6mf4w
5 Dec 22
Prospectus supplement
4:37pm